The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...

The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.

Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® ...

AI for a task that should be done by a physician rather than using it for other burdens that are less worthy than expressing care for patients,” authors of an editorial wrote.

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...

Artificial intelligence (AI) is providing several tools in revolutionising treatment options in neuro-oncology, especially in ...

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and ...

MANILA, Philippines — Heart diseases, neoplasms and stroke were the top three causes of death in the country from January to August of 2024, according to the Philippine Statistics Authority (PSA).

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.